UPATE 1-Dynavax says Merck agrees on final reimbursements

* Merck agrees to pay $4 mln to cover expenses

* Former partnership agreements were related to heplisav

March 15 (BestGrowthStock) – Dynavax Technologies Corp (DVAX.O: )
said Merck & Co Inc (MRK.N: ) agreed to pay $4 million to cover
expenses for the wind-down period that followed Merck’s notice
of termination of a collaboration.

The former partnership agreements covered the clinical
development and commercialization of heplisav, Dynavax’s
experimental hepatitis B vaccine.

In March 2008, U.S. Food and Drug Administration put a
clinical hold on the drug and in December that year, Merck
ended the collaboration.

Heplisav is currently in late-stage trials, after the FDA
removed the clinical hold last September.

The company is developing heplisav for populations that are
less responsive to current licensed vaccines, including
individuals with chronic kidney disease.

Dynavax shares closed at $1.57 Friday on Nasdaq.

Stock Market Report

(Reporting by Jennifer Robin Raj in Bangalore; Editing by
Ratul Ray Chaudhuri)

UPATE 1-Dynavax says Merck agrees on final reimbursements